Further Information
TNFAIP3-interacting protein 1, A20-binding inhibitor of NF-kappa-B activation 1, ABIN-1, HIV-1 Nef-interacting protein, Nef-associated factor 1, Naf1, Nip40-1, Virion-associated nuclear shuttling protein, VAN, hVAN, TNIP1, KIAA0113, NAF1
For WB starting dilution is: 1:1000
Interacts with zinc finger protein A20/TNFAIP3 and inhibits TNF-induced NF-kappa-B-dependent gene expression by interfering with an RIP-or TRAF2-mediated transactivation signal (By similarity). Increases cell surface CD4(T4) antigen expression. Interacts with HIV-1 matrix protein and is packaged into virions and overexpression can inhibit viral replication. May regulate matrix nuclear localization, both nuclear import of PIC (Preintegration complex) and export of GAG polyprotein and viral genomic RNA during virion production.
- He, C.F., et al. Lupus 19(10):1181-1186(2010)
- Rose, J.E., et al. Mol. Med. 16 (7-8), 247-253 (2010) :
- Hosgood, H.D. III, et al. Occup Environ Med 66(12):848-853(2009)
- Gateva, V., et al. Nat. Genet. 41(11):1228-1233(2009)
Supplied in PBS with 0.09% (W/V) sodium azide.
batch dependent
Unconjugated
Optimal dilutions/concentrations should be determined by the end user. The information provided is a guideline for product use. This product is for research use only.
This TNIP1 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 607-636 amino acids from the C-terminal region of human TNIP1.
10318
TNFAIP3-interacting protein 1
TNIP1
Homo sapiens
Liquid
PREDICTED MOLECULAR WEIGHT:
72 kDa
Q15025
20138952
This antibody is purified through a protein A column, followed by peptide affinity purification.
Immunology,Signal Transduction
Q15025
Optimal dilutions for each application to be determined by the researcher.